This study aimed to compare the effects of an SGLT2 inhibitor with an alpha-glucosidase inhibitor on atherogenic risk factors, including high-risk lipid profile and inflammatory markers related to the incidence of ASCVD in diabetes patients with heart failure. This evidence concerns the gene GAA and heart failure.